Heart failure is a condition where reduced levels of adenosine triphosphate (ATP) affect energy supply in myocardial cells. Nicotinamide adenine dinucleotide (NAD⁺) plays a crucial role as a coenzyme for electron transfer in energy metabolism. Decreased NAD⁺ levels in myocardial cells lead to inadequate ATP production and increased susceptibility to heart failure. Researchers are exploring ways to increase NAD⁺ levels to alleviate heart failure. Targets such as sirtuin2 (sirt2), sirtuin3 (sirt3), Poly (ADP-ribose) polymerase (PARP), and diastolic regulatory proteins are being investigated. NAD⁺ supplementation has shown promise, even in heart failure with preserved ejection fraction (HFpEF). By focusing on NAD⁺ as a central component of energy metabolism, it is possible to improve myocardial activity, heart function, and address energy deficiency in heart failure.

CPD can replace CFVAD with pulsatile working modes to a certain extent to treat non-severe HF. The proposed in vitro microfluidic models provided scientific basis for selecting different mechanical circulatory support devices.

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, posing a serious threat to human health. Atherosclerosis (AS), the pathological basis of most cardiovascular diseases, is characterized by arterial wall thickening caused by chronic inflammation. In recent years, molecular probes have attracted much attention as versatile tools for the diagnosis and treatment of AS, offering capabilities in imaging, drug monitoring, and surgical navigation. The existing probes include fluorescent probes, SERS probes, nuclear medicine probes, self-assembled nanoprobes, UC-FRET probes, photothermal probes, and multimodal probes. Among them, fluorescent probes have emerged as a research focus because of their excellent targeting effect, biocompatibility, and multimodal compatibility. This review summarizes recent advances in the classification and synthesis of fluorescent probes, their targeted applications in AS, and their auxiliary diagnosis and treatment of AS. By highlighting current progress and key challenges, this work aims to provide valuable insights to support further development and facilitate the advancement of fluorescent probe technologies in the context of AS, while promoting the clinical application of fluorescent probes.

The complex pathological mechanisms of atherosclerosis (AS) involve lipid metabolism disorders, inflammatory responses, and plaque instability, resulting in significant challenges to effective clinical management. Current therapeutic approaches, such as statins and stent implantation, suffer from issues including single-target action, notable side effects, and the risk of restenosis. Nanoparticle-based drug delivery systems have demonstrated considerable promise by enabling the codelivery of multiple agents directly to atherosclerotic lesions, thereby improving therapeutic efficacy and minimizing systemic toxicity. Among various nanomaterials, organic nanoparticles have recently emerged as a research hotspot in the field of AS treatment due to their excellent biocompatibility, degradability, and potential for targeted modification. This review systematically summarizes the recent advances and emerging trends in the application of organic nanoparticles for AS treatment, employing bibliometric analysis to delineate research frontiers. We employed bibliometric tools to analyze 1999 articles on organic nanocarriers for AS therapy indexed in the Web of Science Core Collection. The analysis included co-occurrence and clustering techniques to explore influential keywords and key contributors. Temporal analysis was applied to identify emerging research hotspots and track the evolution of this field. The literature reveals three major current focal areas: (1) the development of engineered biomimetic organic nanoparticles; (2) the design of multifunctional polymer-based organic nanocarriers; and (3) the innovation of organic-coated stents. This article not only provides a comprehensive overview of cutting-edge organic nanotechnologies for AS therapy, but also critically discusses the challenges in clinical translation, offering insights into future directions for the development of safe, effective, and personalized nanomedicine strategies against AS.

Uncontrolled hemorrhage remains a major challenge in trauma care and surgical interventions, where rapid hemostasis and wound sealing are essential for improving patient survival. Natural polymer-based hydrogels have emerged as promising hemostatic materials owing to their excellent biocompatibility, biodegradability, and biomimetic properties. However, their clinical translation remains limited by insufficient mechanical robustness, wet adhesion, and functional responsiveness. To address these challenges, considerable progress has been achieved through rational material design and structural engineering strategies. Representative natural polymers, particularly polysaccharides and proteins, exhibit distinct physicochemical and biological characteristics that determine their hemostatic mechanisms and design strategies. Based on these material platforms, molecular modification strategies, including charge regulation, hydrophobic modification, and bioactive functionalization, have been widely employed to modulate interfacial interactions, platelet adhesion, coagulation activation, and tissue adhesion. In parallel, advanced structural architectures, such as porous, particulate, fibrous, multicrosslinked/multinetwork, and nanocomposite systems, have significantly enhanced fluid absorption, mechanical resilience, stress dissipation, and hemorrhage sealing efficiency. Beyond conventional hemostasis, increasing efforts have focused on integrating multifunctional properties, including antibacterial activity, inflammatory regulation, oxidative stress modulation, tissue regeneration, dynamic monitoring, and stimuli-responsive behaviors. This review systematically summarizes recent advances in natural polymer-based hemostatic hydrogels from the perspectives of advanced material modification strategies, structural engineering approaches, and functional integration, with particular emphasis on the relationships among material characteristics, interfacial behavior, structural organization, and hemostatic performance. Finally, current challenges and future perspectives for clinical translation are discussed, aiming to provide valuable insights for the rational design and clinical implementation of next-generation hemostatic biomaterials.

Continuous and noninvasive blood pressure (BP) monitoring is important for hypertension screening and long-term cardiovascular management. Continuous BP estimation using photoplethysmography (PPG) and electrocardiography (ECG) has become a promising alternative to conventional cuff-based measurements. However, handcrafted feature-based methods are sensitive to fiducial point detection, while end-to-end deep models often require large labeled datasets and may ignore subject-specific BP baselines. This study proposes a personalized calibration and hybrid feature fusion framework for continuous BP estimation from ECG and PPG signals. The framework integrates physiologically interpretable handcrafted features, self-supervised waveform representations, and subject-specific prior BP information to predict systolic and diastolic BP. The handcrafted branch extracts pulse transit time, heart rate variability, and PPG morphological descriptors, whereas a masked reconstruction-based self-supervised encoder learns latent waveform embeddings without BP labels. Personalized calibration incorporates base BP from the earliest calibration file through an alpha-weighted strategy, and the fused representation is fed into XGBoost regressors. The framework was evaluated on a private dataset and the BP-UCI dataset, achieving SBP/DBP MAEs of 7.25/3.98 mmHg and 7.85/4.02 mmHg, respectively. Comparative and ablation results indicate improved baseline performance in the current experimental setting, suggesting the methodological feasibility of the proposed framework for small-sample continuous BP estimation. Further validation with larger and more diverse cohorts is still required.